Your session is about to expire
← Back to Search
Fenebrutinib vs Teriflunomide for Multiple Sclerosis (FENhance 2 Trial)
FENhance 2 Trial Summary
This trial is testing whether a new drug, fenebrutinib, is better than the current standard of care, teriflunomide, at slowing disability progression and relapse rate in people with RMS.
FENhance 2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowFENhance 2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.FENhance 2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live vaccine in the last 6 weeks.My blood tests show I have low blood cell counts.I can walk 25 feet in less than 150 seconds.I have had cancer, including blood or solid tumors, in the last 10 years.I can complete a manual dexterity test in less than 4 minutes with each hand.I haven't taken hormone or steroid pills or injections in the last 4 weeks.I haven't taken any immune-altering drugs recently without a break.You have had problems with drinking too much alcohol or using drugs in the past year.You cannot undergo an MRI scan.My disability level allows me to walk without aid or rest for 200 meters.If you are a woman who can have children, you agree to not have sex or use birth control methods to avoid getting pregnant during the study. You also agree to not donate eggs.I need long-term steroids or immunosuppressants for another health issue.I have been diagnosed with RMS according to the 2017 guidelines.I do not have HIV or any condition that weakens my immune system.I do not have any major health issues that could affect the study.I agree to not have sex or use birth control and not donate sperm.My disability level is moderate or less.My condition meets the 2017 McDonald Criteria for RMS.I am pregnant, breastfeeding, or planning to become pregnant.I plan to try for a child during the study.My disease has lasted more than 10 years and I have little to no disability.My condition is either primary progressive MS or non-active secondary progressive MS.I do not have any active infections, including Hepatitis B or C, TB, or PML.I have a rare genetic issue with digesting certain sugars.I can walk 25 feet in less than 150 seconds.I have cirrhosis or Gilbert's Syndrome.I agree to not have sex or use birth control and not donate sperm.You have low levels of protein in your blood.I can complete a hand dexterity test in less than 4 minutes for each hand.
- Group 1: Teriflunomide
- Group 2: Fenebrutinib
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research project open to individuals who are below the age of 60?
"This trial, like all medical trials, has age limits for participants. The young age limit is 18 while the upper age limit is 55."
How many facilities are included in this research project?
"28 different hospitals and clinics are participating in this study, with recruitment happening in Detroit, Kansas City, Stanford and 25 other locations. If you're considering enrolling, it might be best to choose a location near you in order to reduce travel."
Could you please list the other instances where fenebrutinib has been studied?
"The medication fenebrutinib was first studied in 2014 at site 056001. To date, there have been 2721 completed trials with 15 more ongoing trials. Many of these active trials are located in Detroit, Michigan."
Has fenebrutinib been cleared by the FDA?
"Fenebrutinib's safety is based on data from previous clinical trials and has been estimated to be a 3 on a scale from 1 to 3."
Have scientists conducted similar research in the past?
"Fenebrutinib has been under clinical investigation since 2014. The first study was sponsored by Genzyme, a Sanofi Company. After the first trial, which included 166 patients, fenebrutinib received Phase 3 drug approval. Today, there are 15 active studies for fenebrutinib being conducted in 62 countries and 346 cities."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger